Literature DB >> 27908801

Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids.

Mirjana Ziemer1, Eleni Koukoulioti2, Susanne Beyer3, Jan C Simon3, Thomas Berg2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27908801     DOI： 10.1016/j.jhep.2016.11.015

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  17 in total

1.  [Supportive therapy and management of side effects in dermato-oncology].

Authors:  Laura von Dücker; Svea Hüning; Katharina Kähler; Patrick Terheyden; Do Ro Thée Nashan
Journal:  Hautarzt       Date:  2019-12       Impact factor: 0.751

2.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544

3.  Hepatobiliary and Pancreatic Adverse Events.

Authors:  Hao Chi Zhang; Lan Sun Wang; Ethan Miller
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials.

Authors:  Yu Fujiwara; Nobuyuki Horita; Matthew Harrington; Ho Namkoong; Hirotaka Miyashita; Matthew D Galsky
Journal:  Cancer Immunol Immunother       Date:  2022-04-26       Impact factor: 6.630

Review 5.  Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology.

Authors:  Julian Hercun; Catherine Vincent; Marc Bilodeau; Pascal Lapierre
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

Review 6.  Hepatotoxicity Induced by Biological Agents: Clinical Features and Current Controversies.

Authors:  Nelia Hernandez; Fernando Bessone
Journal:  J Clin Transl Hepatol       Date:  2022-01-25

7.  Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy.

Authors:  Camila C Simoes; Swan N Thung; Maria Isabel Fiel; Max W Sung; Myron E Schwartz; Stephen C Ward
Journal:  Mod Pathol       Date:  2020-09-28       Impact factor: 7.842

8.  Infliximab for the treatment of refractory immune-related hepatitis secondary to checkpoint inhibitors: A case report.

Authors:  Margaret Corrigan; Geoffrey Haydon; Fiona Thompson; Neil Rajoriya; Claire L Peplow; Stefan G Hubscher; Neil Steven; Gideon M Hirschfield; Matthew J Armstrong
Journal:  JHEP Rep       Date:  2019-04-11

Review 9.  Biologic and Checkpoint Inhibitor-Induced Liver Injury: A Systematic Literature Review.

Authors:  Parth Shah; Vinay Sundaram; Einar Björnsson
Journal:  Hepatol Commun       Date:  2020-01-02

Review 10.  Liver damage related to immune checkpoint inhibitors.

Authors:  Naoshi Nishida; Masatoshi Kudo
Journal:  Hepatol Int       Date:  2019-01-03       Impact factor: 9.029
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.